Details of the Drug
General Information of Drug (ID: DM5ACNU)
Drug Name |
2'-hydroxy-3,4,5-trimethoxychalcone
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Crotaoprostrin; 2'-hydroxy-3,4,5-trimethoxychalcone; CHEMBL521653; 2'-Hydroxy-3,4,5-methoxychalcone; (E)-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; (2E)-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; 59817-22-0; 142955-68-8; NSC331924; AC1NWOUH; MLS001049027; SCHEMBL5423339; MolPort-000-450-785; SRSBUHVXNLHWHU-CMDGGOBGSA-N; HMS2268N22; ZINC4042476; ZX-AT026929; LMPK12120198; STK888527; BDBM50257726; AKOS002181958; NSC-331924; NSC 331924; 2''-hydroxy-3,4,5-trimethoxychalcone; SMR000387055
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 314.3 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.8 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 6 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||